Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa
Could Receive €300m From Private Equity Firm
The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
You may also be interested in...
Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall
The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.
Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.
Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.